It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The COVID-19 pill developed by Merck and Ridgeback Biotherapeutics appears to reduce the risk of hospitalization by inducing mutations in the coronavirus, preventing it from making copies of itself.
...
But in a study led by University of North Carolina researchers earlier this year, the drug also induced low levels of mutations in the DNA of hamster cells — in theory, suggesting it could pose a slight risk of cancer.
...
... — prompting Anthony Fauci, the nation’s chief infectious-disease scientist, to call the results “very impressive.”
How the drug works
Molnupiravir, the drug from Merck and Miami-based Ridgeback, is called a nucleoside analogue. That means its molecules are chemical cousins of one of the building blocks of RNA, the genetic material inside the coronavirus.
The similarity enables the molecules to incorporate themselves into the virus RNA and cause mutations in the process, said Brianne Barker, a Drew University biologist who studies the immune system’s response to viruses.
Merck’s COVID-19 pill and the ‘unknown risk’ of DNA mutation
Some scientists who have studied the drug warn, however, that the method it uses to kill the virus that causes Covid-19 carries potential dangers that could limit the drug’s usefulness.
Molnupiravir works by incorporating itself into the genetic material of the virus, and then causing a huge number of mutations as the virus replicates, effectively killing it. In some lab tests, the drug has also shown the ability to integrate into the genetic material of mammalian cells, causing mutations as those cells replicate.
Merck’s Covid Pill Could Pose Serious Risks, Scientists Warn
originally posted by: myselfaswell
a reply to: MapMistress
I'm thinking of jumping on the bandwagon and making my own Covid drug ...... I was going to call it Getthisinyaloser.
originally posted by: Nexttimemaybe
It doesn't cause the virus to mutate into a new strain as it destroys the virus ability to copy itself.
It says that in the bit you quoted.
Last time I checked, humans were animals. Do Merck scientists not realize that humans are animals too?
In some lab tests, the drug has also shown the ability to integrate into the genetic material of mammalian cells, causing mutations as those cells replicate.
Merck said it plans to double its own production of molnupiravir from 10 million treatment courses in 2021 to at least 20 million in 2022 to meet surging demand for the drug, according to the FT.
Molnupiravir came to Merck through a partnership with a private firm called Ridgeback Biotherapeutics, which licensed the drug from a not-for-profit biotech concern owned by Emory University. Molnupiravir is what’s known as a prodrug, which metabolizes in the body to create NHC, which has been studied for decades.
Schinazi, who is a professor at Emory but did not work on molnupiravir, has a long history with NHC, and has written a number of papers on the compound. He was a founder of the biotech Pharmasset, which he says considered developing NHC as a treatment for hepatitis C in 2003, but chose not to because of the risk that it could cause mutations. Pharmasset created the hepatitis C drug Sovaldi, and Schinazi told Barron’s that he did not believe that molnupiravir should be given to pregnant women, or to young people of reproductive age, until more data is available. Merck’s trials of molnupiravir have excluded pregnant women; the scientists running the trial asked male participants to “abstain from heterosexual intercourse” while taking the drug, according to the federal government website that tracks clinical trials.
A paper published in the Journal of Infectious Diseases in May by Schinazi and scientists at the University of North Carolina reported that NHC caused mutations in animal cell cultures in a lab test designed to detect such mutations.
“The risks for the host may not be zero,” the authors concluded. “Evaluating the utility of this drug should be done in those likely to receive the greatest benefit, with monitoring provided to assess potential long-term genotoxic side effects.” One of the paper’s authors, Dr. Shuntai Zhou, a scientist at the Swanstrom Lab at UNC, said that he and his colleagues had flagged their initial findings to Merck in July 2020, roughly a year before his paper was published. “There is a concern that this will cause long-term mutation effects, even cancer,” Zhou says. Zhou says that he is certain that the drug will integrate itself into the DNA of mammalian hosts. “Biochemistry won’t lie,” he says. “This drug will be incorporated in the DNA.” What impact it will have when it’s there is unknown, given the various systems human cells use to limit the impact of mutations.
originally posted by: Nexttimemaybe
It doesn't cause the virus to mutate into a new strain as it destroys the virus ability to copy itself.
It says that in the bit you quoted.
originally posted by: Nexttimemaybe
It doesn't cause the virus to mutate into a new strain as it destroys the virus ability to copy itself.
It says that in the bit you quoted.
originally posted by: Nexttimemaybe
It doesn't cause the virus to mutate into a new strain as it destroys the virus ability to copy itself.
It says that in the bit you quoted.